Annual SG&A
$19.75 B
+$1.82 B+10.15%
31 December 2023
Summary:
AstraZeneca annual selling, general & administrative expenses is currently $19.75 billion, with the most recent change of +$1.82 billion (+10.15%) on 31 December 2023. During the last 3 years, it has risen by +$7.86 billion (+66.06%). AZN annual SG&A is now at all-time high.AZN Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$5.29 B
+$227.00 M+4.49%
30 September 2024
Summary:
AstraZeneca quarterly selling, general & administrative expenses is currently $5.29 billion, with the most recent change of +$227.00 million (+4.49%) on 30 September 2024. Over the past year, it has increased by +$359.00 million (+7.28%). AZN quarterly SG&A is now at all-time high.AZN Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
$6.28 B
+$3.57 B+132.15%
30 September 2024
Summary:
AstraZeneca TTM selling, general & administrative expenses is currently $6.28 billion, with the most recent change of +$3.57 billion (+132.15%) on 30 September 2024. Over the past year, it has dropped by -$11.77 billion (-65.23%). AZN TTM SG&A is now -91.35% below its all-time high of $19.33 billion, reached on 30 September 2022.AZN TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AZN Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10.2% | +7.3% | -65.2% |
| 3 y3 years | +66.1% | +25.6% | -55.0% |
| 5 y5 years | +79.9% | +60.9% | -49.1% |
AZN Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +66.1% | at high | +38.9% | -62.9% | +196.1% |
| 5 y | 5 years | at high | +79.9% | at high | +93.1% | -62.9% | +196.1% |
| alltime | all time | at high | >+9999.0% | at high | +665.9% | -91.3% | +196.1% |
AstraZeneca Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $5.29 B(+4.5%) | $18.96 B(+1.9%) |
| June 2024 | - | $5.06 B(+9.3%) | $18.60 B(-0.3%) |
| Mar 2024 | - | $4.63 B(+16.2%) | $18.66 B(+2.4%) |
| Dec 2023 | $19.75 B(+10.1%) | $3.98 B(-19.2%) | $18.22 B(+1.0%) |
| Sept 2023 | - | $4.93 B(-3.7%) | $18.05 B(+3.0%) |
| June 2023 | - | $5.12 B(+22.0%) | $17.52 B(+1.8%) |
| Mar 2023 | - | $4.19 B(+10.2%) | $17.21 B(-4.3%) |
| Dec 2022 | $17.93 B(+15.1%) | $3.81 B(-13.6%) | $17.98 B(-7.0%) |
| Sept 2022 | - | $4.40 B(-8.5%) | $19.33 B(+1.0%) |
| June 2022 | - | $4.81 B(-3.1%) | $19.14 B(+9.2%) |
| Mar 2022 | - | $4.96 B(-3.6%) | $17.53 B(+12.4%) |
| Dec 2021 | $15.59 B(+31.0%) | $5.15 B(+22.4%) | $15.59 B(+11.7%) |
| Sept 2021 | - | $4.21 B(+31.5%) | $13.96 B(+11.0%) |
| June 2021 | - | $3.20 B(+5.7%) | $12.58 B(+3.8%) |
| Mar 2021 | - | $3.03 B(-14.0%) | $12.12 B(+1.9%) |
| Dec 2020 | $11.90 B(-0.7%) | $3.52 B(+24.5%) | $11.90 B(+3.8%) |
| Sept 2020 | - | $2.83 B(+3.3%) | $11.46 B(-3.8%) |
| June 2020 | - | $2.74 B(-2.4%) | $11.91 B(-2.3%) |
| Mar 2020 | - | $2.81 B(-9.0%) | $12.20 B(+1.8%) |
| Dec 2019 | $11.98 B(+9.1%) | $3.08 B(-6.2%) | $11.98 B(-2.8%) |
| Sept 2019 | - | $3.29 B(+8.7%) | $12.33 B(+7.1%) |
| June 2019 | - | $3.02 B(+16.7%) | $11.51 B(+3.5%) |
| Mar 2019 | - | $2.59 B(-24.3%) | $11.12 B(+0.5%) |
| Dec 2018 | $10.98 B(+4.2%) | $3.42 B(+38.6%) | $11.07 B(+2.4%) |
| Sept 2018 | - | $2.47 B(-6.3%) | $10.81 B(-0.9%) |
| June 2018 | - | $2.63 B(+3.8%) | $10.91 B(+1.9%) |
| Mar 2018 | - | $2.54 B(-19.8%) | $10.70 B(+1.5%) |
| Dec 2017 | $10.54 B(+8.3%) | $3.16 B(+22.9%) | $10.54 B(+19.1%) |
| Sept 2017 | - | $2.57 B(+5.9%) | $8.85 B(+1.1%) |
| June 2017 | - | $2.43 B(+2.2%) | $8.76 B(-7.5%) |
| Mar 2017 | - | $2.38 B(+61.8%) | $9.47 B(-2.8%) |
| Dec 2016 | $9.74 B(-15.4%) | $1.47 B(-40.7%) | $9.74 B(-12.3%) |
| Sept 2016 | - | $2.48 B(-21.1%) | $11.10 B(-2.5%) |
| June 2016 | - | $3.14 B(+18.7%) | $11.38 B(+0.8%) |
| Mar 2016 | - | $2.65 B(-6.5%) | $11.29 B(-2.0%) |
| Dec 2015 | $11.52 B(-13.6%) | $2.83 B(+2.7%) | $11.52 B(-10.4%) |
| Sept 2015 | - | $2.76 B(-9.6%) | $12.86 B(-3.5%) |
| June 2015 | - | $3.05 B(+6.1%) | $13.32 B(-0.6%) |
| Mar 2015 | - | $2.88 B(-31.1%) | $13.40 B(+0.6%) |
| Dec 2014 | $13.32 B(+6.5%) | $4.17 B(+29.6%) | $13.32 B(-3.9%) |
| Sept 2014 | - | $3.22 B(+2.7%) | $13.87 B(+4.8%) |
| June 2014 | - | $3.13 B(+12.0%) | $13.23 B(+4.1%) |
| Mar 2014 | - | $2.80 B(-40.6%) | $12.71 B(+1.6%) |
| Dec 2013 | $12.51 B(+23.2%) | $4.71 B(+82.4%) | $12.51 B(+18.6%) |
| Sept 2013 | - | $2.58 B(-1.3%) | $10.55 B(+1.3%) |
| June 2013 | - | $2.62 B(+0.9%) | $10.41 B(+1.9%) |
| Mar 2013 | - | $2.60 B(-5.6%) | $10.22 B(+0.6%) |
| Dec 2012 | $10.16 B(-11.7%) | $2.75 B(+12.2%) | $10.16 B(-4.5%) |
| Sept 2012 | - | $2.45 B(+1.0%) | $10.64 B(-2.6%) |
| June 2012 | - | $2.42 B(-4.4%) | $10.93 B(-4.6%) |
| Mar 2012 | - | $2.54 B(-21.4%) | $11.46 B(-0.4%) |
| Dec 2011 | $11.51 B(+6.7%) | $3.23 B(+17.9%) | $11.51 B(+5.7%) |
| Sept 2011 | - | $2.74 B(-7.4%) | $10.89 B(-3.2%) |
| June 2011 | - | $2.96 B(+14.2%) | $11.25 B(+3.9%) |
| Mar 2011 | - | $2.59 B(-0.8%) | $10.83 B(+0.4%) |
| Dec 2010 | $10.78 B | $2.61 B(-15.6%) | $10.78 B(-8.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | $3.09 B(+21.9%) | $11.73 B(+3.1%) |
| June 2010 | - | $2.54 B(-0.1%) | $11.37 B(-3.1%) |
| Mar 2010 | - | $2.54 B(-28.6%) | $11.73 B(+0.9%) |
| Dec 2009 | $11.63 B(+3.8%) | $3.56 B(+30.0%) | $11.63 B(+2.2%) |
| Sept 2009 | - | $2.74 B(-5.6%) | $11.38 B(+2.7%) |
| June 2009 | - | $2.90 B(+18.8%) | $11.08 B(+1.3%) |
| Mar 2009 | - | $2.44 B(-26.2%) | $10.94 B(-2.4%) |
| Dec 2008 | $11.20 B(+5.6%) | $3.31 B(+35.8%) | $11.20 B(-0.6%) |
| Sept 2008 | - | $2.43 B(-11.8%) | $11.27 B(-1.2%) |
| June 2008 | - | $2.76 B(+2.0%) | $11.40 B(+3.3%) |
| Mar 2008 | - | $2.71 B(-19.7%) | $11.04 B(+4.0%) |
| Dec 2007 | $10.61 B(+13.8%) | $3.37 B(+31.1%) | $10.61 B(+6.3%) |
| Sept 2007 | - | $2.57 B(+7.2%) | $9.98 B(+4.1%) |
| June 2007 | - | $2.40 B(+5.2%) | $9.59 B(+1.1%) |
| Mar 2007 | - | $2.28 B(-16.8%) | $9.48 B(+1.7%) |
| Dec 2006 | $9.32 B(+4.7%) | $2.74 B(+25.6%) | $9.32 B(+1.3%) |
| Sept 2006 | - | $2.18 B(-4.8%) | $9.20 B(+1.4%) |
| June 2006 | - | $2.29 B(+8.3%) | $9.07 B(+0.7%) |
| Mar 2006 | - | $2.12 B(-19.1%) | $9.01 B(+1.2%) |
| Dec 2005 | $8.91 B(+5.5%) | $2.61 B(+27.1%) | $8.91 B(+5.1%) |
| Sept 2005 | - | $2.06 B(-7.8%) | $8.47 B(+0.5%) |
| June 2005 | - | $2.23 B(+11.1%) | $8.43 B(+0.3%) |
| Mar 2005 | - | $2.01 B(-8.1%) | $8.41 B(+0.0%) |
| Dec 2004 | $8.45 B(+11.8%) | $2.18 B(+8.6%) | $8.40 B(-4.0%) |
| Sept 2004 | - | $2.01 B(-8.8%) | $8.75 B(+1.9%) |
| June 2004 | - | $2.21 B(+10.1%) | $8.59 B(+7.0%) |
| Mar 2004 | - | $2.00 B(-20.9%) | $8.03 B(+6.3%) |
| Dec 2003 | $7.55 B(+23.1%) | $2.53 B(+36.8%) | $7.56 B(+10.5%) |
| Sept 2003 | - | $1.85 B(+12.7%) | $6.83 B(+7.2%) |
| June 2003 | - | $1.64 B(+7.5%) | $6.38 B(+2.0%) |
| Mar 2003 | - | $1.53 B(-15.6%) | $6.25 B(+1.9%) |
| Dec 2002 | $6.14 B(+10.6%) | $1.81 B(+30.0%) | $6.14 B(+5.8%) |
| Sept 2002 | - | $1.39 B(-8.3%) | $5.80 B(+0.7%) |
| June 2002 | - | $1.52 B(+7.5%) | $5.76 B(+2.7%) |
| Mar 2002 | - | $1.41 B(-4.2%) | $5.61 B(+1.8%) |
| Dec 2001 | $5.55 B(+6091.9%) | $1.48 B(+9.1%) | $5.51 B(+36.5%) |
| Sept 2001 | - | $1.35 B(-1.2%) | $4.04 B(+3.0%) |
| June 2001 | - | $1.37 B(+4.0%) | $3.92 B(+2.9%) |
| Mar 2001 | - | $1.32 B(+6.7%) | $3.81 B(-18.1%) |
| Dec 2000 | $89.62 M(-98.2%) | - | - |
| Sept 2000 | - | $1.23 B(-1.9%) | $4.65 B(+0.9%) |
| June 2000 | - | $1.26 B(+3.4%) | $4.61 B(-2.8%) |
| Mar 2000 | - | $1.22 B(+28.9%) | $4.74 B(+34.5%) |
| Dec 1999 | $4.92 B(+24.9%) | $944.00 M(-20.9%) | $3.53 B(+36.6%) |
| Sept 1999 | - | $1.19 B(-14.1%) | $2.58 B(+85.9%) |
| June 1999 | - | $1.39 B(+47.8%) | $1.39 B(+47.8%) |
| Dec 1998 | $3.94 B(>+9900.0%) | - | - |
| June 1998 | - | $939.50 M(+36.1%) | $939.50 M(+36.1%) |
| Dec 1997 | $36.37 M(-3.5%) | - | - |
| Dec 1996 | $37.68 M(-18.7%) | - | - |
| Dec 1995 | $46.36 M(-17.6%) | - | - |
| June 1995 | - | $690.40 M | $690.40 M |
| Dec 1994 | $56.28 M(+8.7%) | - | - |
| Dec 1993 | $51.77 M(+6.7%) | - | - |
| Dec 1992 | $48.53 M(-3.9%) | - | - |
| Dec 1991 | $50.52 M(+4.8%) | - | - |
| Dec 1990 | $48.22 M | - | - |
FAQ
- What is AstraZeneca annual selling, general & administrative expenses?
- What is the all time high annual SG&A for AstraZeneca?
- What is AstraZeneca annual SG&A year-on-year change?
- What is AstraZeneca quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for AstraZeneca?
- What is AstraZeneca quarterly SG&A year-on-year change?
- What is AstraZeneca TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for AstraZeneca?
- What is AstraZeneca TTM SG&A year-on-year change?
What is AstraZeneca annual selling, general & administrative expenses?
The current annual SG&A of AZN is $19.75 B
What is the all time high annual SG&A for AstraZeneca?
AstraZeneca all-time high annual selling, general & administrative expenses is $19.75 B
What is AstraZeneca annual SG&A year-on-year change?
Over the past year, AZN annual selling, general & administrative expenses has changed by +$1.82 B (+10.15%)
What is AstraZeneca quarterly selling, general & administrative expenses?
The current quarterly SG&A of AZN is $5.29 B
What is the all time high quarterly SG&A for AstraZeneca?
AstraZeneca all-time high quarterly selling, general & administrative expenses is $5.29 B
What is AstraZeneca quarterly SG&A year-on-year change?
Over the past year, AZN quarterly selling, general & administrative expenses has changed by +$359.00 M (+7.28%)
What is AstraZeneca TTM selling, general & administrative expenses?
The current TTM SG&A of AZN is $6.28 B
What is the all time high TTM SG&A for AstraZeneca?
AstraZeneca all-time high TTM selling, general & administrative expenses is $19.33 B
What is AstraZeneca TTM SG&A year-on-year change?
Over the past year, AZN TTM selling, general & administrative expenses has changed by -$11.77 B (-65.23%)